Anda Repository Company Profile
What is the competitive landscape for ANDA REPOSITORY
ANDA REPOSITORY has thirteen approved drugs.
Drugs and US Patents for Anda Repository
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anda Repository | PREGABALIN | pregabalin | SOLUTION;ORAL | 212604-001 | Feb 18, 2022 | AA | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Anda Repository | CEFDINIR | cefdinir | FOR SUSPENSION;ORAL | 065429-001 | Jul 18, 2007 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Anda Repository | MORPHINE SULFATE | morphine sulfate | CAPSULE, EXTENDED RELEASE;ORAL | 203158-001 | Aug 4, 2021 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.

